XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
Kurt A Jenkins, Miso Park, Magali Pederzoli-Ribeil, Ugur Eskiocak, Parker Johnson, Wilson Guzman, Megan McLaughlin, Deborah Moore-Lai, Caitlin O’Toole, Zhen Liu, Benjamin Nicholson, Veronica Flesch, Huawei Qiu, Tim Clackson, Ronan C O’Hagan, Ulrich Rodeck, Margaret Karow, Jennifer O’Neil, John C Williams
Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e007785; DOI: 10.1136/jitc-2023-007785